At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
Niraparib + Nivolumab +1 moredrug
Likely dose
Niraparib + Nivolumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy
In Brief
A Phase 2 clinical trial evaluating Niraparib + Nivolumab and Niraparib + Ipilimumab for Pancreatic Adenocarcinoma. Completed, enrolled 104 participants across 1 site.
Detailed Summary
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on patients and their pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Adenocarcinoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, GlaxoSmithKline
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartJan 2018
Primary CompletionApr 2022
Study CompletionOct 2024
TodayJul 2026
First PostedJan 19, 2018
Enrollment StartJan 31, 2018
Primary CompletionApr 5, 2022
Study CompletionOct 9, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.5 years ago
Interventions
Niraparib + Nivolumabdrug
Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
Niraparib + Ipilimumabdrug
Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.